There is one clinical trial.
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Description: percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19Measure: intensive care treatment Time: 9 months
Description: ICU stay timesMeasure: ICU stay times Time: 9 months
Description: percentage of patients who died 1 month after treatmentMeasure: % died after 1 month after treatment Time: 9 months
Description: time of hospitalizationMeasure: hospitalization Time: 9 months
Description: number of adverse eventMeasure: adverse event Time: 9 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports